Clinical Trials

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02180724 2025-11-26

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

107 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT02477696 2025-11-20

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06428019 2025-11-05

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 3 Recruiting

170 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05951959 2025-10-21

TrAVeRse

108 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

113 enrolled 19 charts

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

35 enrolled

Part1: Advanced B-cell Malignancies

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 1 FDA

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02157324 2025-08-13

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06839872 2025-06-05

BOSS

Phase 2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04662255 2025-05-28

BRUIN-MCL-321

500 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

Phase 1/2 Terminated

60 enrolled 20 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04419389 2025-03-17

R/R

Phase 1/2 Terminated

1 enrolled 4 charts

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 1 FDA

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

21 enrolled 11 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04930536 2024-11-22

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Phase 4 Completed

103 enrolled 10 charts

Other hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Hematologic Neoplasms

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Phase 2 Terminated

41 enrolled 4 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03527147 2022-08-15

PRISM

30 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Phase 1/2 Terminated

25 enrolled 11 charts

DLBCL

NCT04564040 2020-12-29

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

20 enrolled

COVID-19, Lymphoma, Mantle-Cell

NCT02211014 2020-07-31

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma